Foff Erin Pennock
Known title: Chief Medical OfficerCIK: 0002021233
Associated companies
Transaction History
| MPLT | ▲ Buy | Grant | 13,360 | $0 | 8/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 3,656 | $139K | 7/17/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 9,163 | $334K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,865 | $219K | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 19 | $721 | 7/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 7,155 | $259K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 7,845 | $291K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 4,465 | $161K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 8,972 | $332K | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 18 | $676 | 7/15/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 4,321 | $123K | 5/7/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 117 | $3K | 5/7/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 8,152 | $229K | 5/6/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 15,900 | $463K | 5/6/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 9,645 | $271K | 5/5/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 931 | $27K | 5/5/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 9,180 | $252K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 5,460 | $155K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 312 | $9K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 700 | $21K | 5/4/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 288 | $8K | 4/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 881 | $24K | 4/16/2026 | View on chart |
| MPLT | ▼ Sell | Open Market | 2,044 | $55K | 4/15/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 13,360 | $0 | 2/5/2026 | View on chart |
| MPLT | ▼ Sell | Tax Withholding | 44,616 | $802K | 1/27/2026 | View on chart |
| MPLT | ▲ Buy | Grant | 48,275 | $0 | 10/27/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
MapLight Therapeutics Shares Fall 34.8% in Four Weeks
MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.
MapLight Therapeutics Shares Fall 34.8% in Four Weeks. MapLight Therapeutics stock has dropped 34.8% over the past month, leading some market observers to discuss potential for a turnaround. The decline places the stock near its 52-week low of $8.70, while the current RSI of 21.9 suggests the shares are in oversold territory. Analysts maintain an average price target of $26.54, indicating a wide range of expectations for the company's future performance.